BioPharma Credit PLC (BPCR) - Total Liabilities
Based on the latest financial reports, BioPharma Credit PLC (BPCR) has total liabilities worth $7.49 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BPCR shareholders equity momentum to track the company's year-over-year net asset growth rate.
BioPharma Credit PLC - Total Liabilities Trend (2017–2024)
This chart illustrates how BioPharma Credit PLC's total liabilities have evolved over time, based on quarterly financial data. See BPCR free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
BioPharma Credit PLC Competitors by Total Liabilities
The table below lists competitors of BioPharma Credit PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ORION Holdings Corp
KO:001800
|
Korea | ₩1.03 Trillion |
|
Fras-le S.A
SA:FRAS3
|
Brazil | R$4.46 Billion |
|
Saregama India Limited
NSE:SAREGAMA
|
India | Rs6.65 Billion |
|
SFL Corporation Ltd
NYSE:SFL
|
USA | $2.86 Billion |
|
Genco Shipping & Trading Ltd
NYSE:GNK
|
USA | $365.01 Billion |
|
Northeast Bancorp
NASDAQ:NBN
|
USA | $4.47 Billion |
|
Guilin Fuda Co Ltd
SHG:603166
|
China | CN¥2.16 Billion |
|
Jingjin Environmental Protection Co Ltd
SHG:603279
|
China | CN¥4.12 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down BioPharma Credit PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BioPharma Credit PLC (BPCR) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioPharma Credit PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioPharma Credit PLC (2017–2024)
The table below shows the annual total liabilities of BioPharma Credit PLC from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.94 Million | +13.03% |
| 2023-12-31 | $15.87 Million | -39.66% |
| 2022-12-31 | $26.30 Million | +281.17% |
| 2021-12-31 | $6.90 Million | -26.54% |
| 2020-12-31 | $9.39 Million | -62.78% |
| 2019-12-31 | $25.23 Million | +90.44% |
| 2018-12-31 | $13.25 Million | +354.42% |
| 2017-12-31 | $2.92 Million | -- |
About BioPharma Credit PLC
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in Leeds, the United Kingdom.